MRSA Detection : 6 Hours
Group B Strep Detection : ± 6 Hours
E. coli Detection : 4 Hours
Anthrax Detection : ± 1 Hour
RAPID DETECTION OF VIABLE MICROORGANISMS
NanoLogix® NanoLogix BNP Petri-based sandwiched-membrane kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology. NanoLogix FlatPack packaging allows for an extended shelf-life for both our Petri plates and our BNP kits that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix Petri plates containing TSA media in FlatPacks® have maintained viability for nutrient and moisture levels for over three years in cold storage and over two years at room temperature (RT), as compared to 3-1/2 months of useable shelf life for competitive products that require refrigeration. Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures. All of the Petri plates and BNP Petri kits NanoLogix produces are packaged in FlatPack packaging to ensure the longest useable shelf life, with most of the FlatPacks we produce undergoing a further electron-beam (e-beam) processing step to provide customers with the best product for their use with an extremely long shelf life.
NanoLogix®, Inc. is a biotechnology company specializing in live cell, rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, national defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
Stock Symbol: NNLX
COMPANY OPERATIONS SUMMARY
May 04, 2015
2015 Update Pending
07.08.14 00:05 Nanologix® News wire:
NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
NanoLogix Inc. (NNLX), an innovator in the rapid detection of viable bacteria, and identification and determination of antibiotic resistance/sensitivity of those bacteria, announces that it is exhibiting at the BioOhio BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at the Bertram Conference Center. Sebastian Faro MD., PhD, a highly recognized authority on infectious diseases of female reproductive systems, will be presenting on the NanoLogix N-Assay Multiwell Microplate Assay during the event. NanoLogix is also a sponsor of the Expo. There is no charge for admission. Further information is available by following this link
The European Patent Office has informed our London and US Patent Law firms that our European application for the NanoLogix BNP sandwiched-membrane Petri based detection technology has received an allowance for grant under the European Patent Convention. The patent will cover up to 38 member countries, dependent upon NanoLogix’s election, and significantly enhances the NanoLogix Patent Portfolio. The BNP technology received patent grants in 2013 in both Japan and Russia and is currently patent pending in the United States.
At the American Society for Microbiology (ASM) annual meeting in late May, NanoLogix's display booth was visited by NASA. Upon viewing the NanoLogix Petri plates vacuum packed in nitrogen-charged FlatPacks, the following comment was made: “This is exactly what we’ve been looking for. We’re sending these up there,” referring to the International Space Station (ISS). In early June, at NASA’s request, NanoLogix supplied NASA with a number of Petri and BNP FlatPacks for their use. The company is currently awaiting further information from NASA and will release additional news as appropriate. The qualities that are of interest to NASA are the robust nature of the Petri dishes packaged in the patented FlatPack with enhanced durability and resistance to breakage, coupled with the long term room-temperature shelf life of at least two years, compared to the competition’s shelf life of 3-1/2 months refrigerated.
06.27.14 11:15 Nanologix® News:
Nanologix granted an European patent
The European Patent Office has informed our London and US Patent Law firms that our European application for the BNP has been granted as a European Patent under the European Patent Convention. The 38 member states where this patent applies are: Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Turkey, Bulgaria, Czech Republic, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Malta, Croatia, Norway, Former Yugoslav Republic of Macedonia, San Marino, Albania, and Serbia. With the EU Patent grant, NanoLogix is electing to file for national patent issuance in the majority of the covered countries with some exceptions. This BNP patent grant joins the NanoLogix portfolio of patents for the BNP granted in Japan and Russia, and when each member state patent is issued to NanoLogix will dramatically increase the number of granted patents in our portfolio.
06.04.14 05:05 Nanologix® News:
YSU business students learn by doing
NanoLogix is pleased to have been mentioned in a news update from Youngstown State University's Williamson College of Business Administration. The update focused upon the participation of seven area companies that worked with students on their Exporting Course projects for assessing international marketing potential. The assessments were performed utilizing a powerful marketing resource database available through the University and the State of Ohio. The management and staff of NanoLogix, as a member of the local business community and as a current exporter to a number of countries, view participation in educational projects such as this as part of their duty to that community. We are pleased to have been able to contribute to the education of students about to enter their business careers. more>>>
05.20.14 01:05 Nanologix® NewsWire: Nanologix Exhibits at ASM Annual Meeting in Boston and welcomes VP for Sales and Marketing Read more>>>
04.14.14 00:05 Nanologix® News: NanoLogix's new N-Assay rapid test discussed in article by Dr. Jonathan Faro in latest issue of Med Lab Observer Read more>>>
01.27.14 00:05 Nanologix® News: State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution Agreements Read more>>>
12.04.13 12:02 Nanologix® News: Announces additional product offerings with E-Beam sterilization process - NanoLogix and Saudi Company To Work Together for Distribution of NanoLogix Products in the Arabian Gulf Region Read more>>>
06.21.13 NanoLogix BNP Instructional Video
06.11.13 02:31 Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>
NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver. Read more>>>
04.02.13 10:29 Nanologix® News:NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world..
03.13.13 10:29 Nanologix® News:UTHealth researchers say more rapid test for Group B strep successful. Read more>>>
11.09.12 Nanologix® News: NanoLogix Subject of EPA Featured News article. Read more>>
6.13.12 Health News Texas: Texas Health Science Center-Huston instrumental in New NanoLogix Technology Read the article>>
SIGN UP FOR eNEWS
Oct 26, 2015:
NanoLogix BioTechnology announces:
1) The completion of N-Assay primary research by researchers in Houston, Texas. The research paper is being finalized for submission to a noted peer-reviewed journal. The research was on three bacteria --- Neisseria Gonorrhea, Group B Streptococcus, and Enterococcus and was focused upon their rapid detection, identification, and the determination of their antibiotic resistance and sensitivity to multiple antibiotics. The results, in a few words, are: very positive, huge, phenomenal, great, unprecedented , to say the least. The N-Assay appears to work rapidly to identify any bacteria for which there exists an antibody.
2) With the delivery today of 100,000+ petri plates, NanoLogix Biotechnology has moved exclusively to using petri plates from Gosselin (A Corning company). The Gosselin products, previously purchased by the Company in 50,000+ plate lots, have enabled the company to increase economy of scale by 20% over other manufacturers' products more>>>
July 1, 2015:
BNF Patent Granted - US Patent #9,068,216
The Company is pleased to announce the United States Patent and Trademark Office has granted U.S. Patent 9,068,216 on 30 June 2015 for: Methods and devices for rapid detection and identification of live microorganisms by aptamers and/or antibodies immobilized on permeable membranes more>>>
June 17, 2015:
Notification received from Peoples Republic of China for grant of FlatPack packaging patent
In early June, notification of "Grant Patent Right for Invention" was received from the China Patent intellectual Property Office in Beijing more>>>
June 16, 2015:
NanoLogix expands choices for order configuration
In order to better satisfy customer needs, effective July 1, 2015, NanoLogix will offer Flatpack petri plate configurations in Flatpacks of 20, 30, 40 and 50 plates in addition to the standard 10 and 25 plates currently supplied. This move is done to assist high-use current and potential customers in reducing both their labor for handling in the laboratory and overall packaging waste disposal costs. The company anticipates this move will further increase the attractiveness of NanoLogix petri plates to present and potential customers.
May 04, 2015:
Rapid Tests for Fungal Infections The industry demands diagnostic tests that are fast, sensitive and easy to use more>>>
Feb 11, 2015:
NanoLogix is pleased to announce receipt of notification of allowance and/or granting of patents in the US and internationally for USA: BNF for use with Antibodies and Aptamers USA: N-Assay Rapid Detection Technology China: FlatPack Packaging New Zealand: FlatPack Packaging The allowance and upcoming grants of patents significantly strengthen the position of the Company's intellectual property both domestically and internationally
Jan 14, 2015:
NanoLogix is pleased to share the following information: In recent and ongoing work, researchers in the United States have confirmed the potential efficacy of NanoLogix's N-Assay as a rapid indicator for the presence of the current-threat strain of the Ebola virus, EBOV. The research demonstrates a sub-three hour result at present. Researchers are working to refine the test and reduce time-to-detection to facilitate the N-Assay's use as a Point of Care (POC) diagnostic for hemorrhagic and other viruses.
Nov 4, 2014:
Ebola epidemic spurs hunt for new, faster tests more>>>
Oct 14, 2014:
NanoLogix Technology Being Configured For Rapid Ebola Virus Detection more>>>
Sep 29, 2014:
NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization more>>>
Sep 19, 2014:
NanoLogix is very pleased to announce that The Ohio State University has issued a Purchase Order (PO) to NanoLogix Incorporated to supply the University with the following:
- Gel culture media
- Cell culture supplements
- Biochemical reagents
- Cell preservation/growth supplies
This PO runs from September 17, 2014 to June 30, 2015 and is a blanket Purchase Order for lab supplies.
Aug 6, 2014:
Dr. Sebastian Faro's presentation video on NanoLogix BNF and N-Assay technologies more>>>
Aug 4, 2014:
Third party tests result surpasses Nanologix's competition
NanoLogix received notification at the end of July of results for two time and temperature related tests that have been performed by a renowned independent third-party lab. more>>>